PapersFlow Research Brief
Pancreatic function and diabetes
Research Guide
What is Pancreatic function and diabetes?
Pancreatic function and diabetes is the study of how endocrine pancreatic islet biology—especially β-cell insulin secretion and its regulation—fails or adapts in diabetes mellitus and how those mechanisms can be therapeutically targeted to restore glucose homeostasis and reduce complications.
The literature cluster on pancreatic function and diabetes comprises 132,706 works, emphasizing pancreatic islets, β-cell dysfunction, insulin secretion, glucose homeostasis, and therapeutic strategies including pharmacology and islet replacement approaches. Highly cited clinical outcomes trials in type 2 diabetes show that glucose-lowering therapies can also modify cardiovascular and renal outcomes, as demonstrated in "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes" (2016) and "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes" (2017). Mechanistic foundations relevant to β-cell stress and survival are frequently linked to cellular pathways such as the unfolded protein response ("Signal integration in the endoplasmic reticulum unfolded protein response" (2007)) and autophagy regulation ("AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1" (2011)).
Topic Hierarchy
Research Sub-Topics
Beta-Cell Dysfunction Diabetes
This sub-topic investigates molecular mechanisms of ß-cell failure in type 2 diabetes, including glucotoxicity and lipotoxicity. In vitro and animal models dissect signaling defects.
Insulin Secretion Mechanisms
Researchers elucidate stimulus-secretion coupling in pancreatic islets, focusing on calcium dynamics and exocytosis. Electrophysiology and imaging reveal nutrient and incretin regulation.
Pancreatic Islet Transplantation
Clinical trials optimize allogeneic and autologous islet infusions for glycemic independence in type 1 diabetes. Studies address immunosuppression and engraftment barriers.
Stem Cell Differentiation Beta Cells
This area develops protocols for directing pluripotent stem cells into functional insulin-producing cells. Scalability and maturity assessments guide translational efforts.
Glucose Homeostasis Pancreatic Regulation
Integrated studies model bihormonal control of glycemia by alpha and beta cells under physiological and diabetic stress. Mathematical simulations predict therapeutic perturbations.
Why It Matters
Pancreatic islet dysfunction is clinically consequential because impaired insulin secretion and β-cell failure contribute directly to hyperglycemia and to the downstream complications that drive morbidity in diabetes care. Large cardiovascular–renal outcomes trials provide concrete examples of how targeting glucose handling can change clinically meaningful endpoints beyond HbA1c: "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes" (2017) evaluated cardiovascular, renal, and safety outcomes with an SGLT2 inhibitor, and "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy" (2019) reported lower risks of kidney failure and cardiovascular events with canagliflozin versus placebo with a median follow-up of 2.62 years. Similarly, "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes" (2018) reported a lower rate of cardiovascular death or hospitalization for heart failure with dapagliflozin, and "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction" (2019) found reduced risk of worsening heart failure or cardiovascular death regardless of diabetes status, underscoring that diabetes therapies can act through systemic physiology that intersects with pancreatic endocrine dysfunction. At the mechanistic level, β-cell failure is often studied through stress-response pathways that affect insulin production and cell survival; "Signal integration in the endoplasmic reticulum unfolded protein response" (2007) is widely used to frame how ER stress signaling can influence secretory cells, while "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1" (2011) provides a canonical entry point for understanding how nutrient sensing can regulate autophagy, a process frequently invoked in models of β-cell adaptation and failure.
Reading Guide
Where to Start
Start with Ron and Walter’s "Signal integration in the endoplasmic reticulum unfolded protein response" (2007) because it provides a unifying mechanistic vocabulary for secretory-cell stress that is repeatedly invoked when interpreting β-cell dysfunction and loss.
Key Papers Explained
A mechanistic-to-clinical throughline can be built by connecting cellular stress and survival biology to outcomes trials. Ron and Walter’s "Signal integration in the endoplasmic reticulum unfolded protein response" (2007) frames how stress signaling is integrated in the ER, a core concept for insulin-producing cells; Kim et al.’s "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1" (2011) adds a nutrient-sensing mechanism that frequently underpins hypotheses about β-cell adaptation. These mechanistic concepts sit upstream of clinical phenotypes addressed in outcomes trials: "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes" (2016) evaluates an incretin-based therapy with cardiovascular endpoints, while "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes" (2017), "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes" (2018), and "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy" (2019) show how glucose-lowering therapies relate to cardiovascular and kidney outcomes that diabetes researchers must explain mechanistically.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
For advanced reading focused on translation, compare the endpoint structures and population framing across "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes" (2017), "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes" (2018), and "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy" (2019), then explicitly map candidate mechanisms back to the cellular control nodes in "Signal integration in the endoplasmic reticulum unfolded protein response" (2007) and "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1" (2011). A second advanced direction is to use "Positional cloning of the mouse obese gene and its human homologue" (1994) to anchor discussions about how systemic energy balance signals modulate insulin demand and β-cell stress trajectories.
Papers at a Glance
In the News
Syntax Bio Receives Award from Breakthrough T1D to ...
# Syntax Bio Receives Award from Breakthrough T1D to Advance Pancreatic Beta Cell Therapy for Type 1 Diabetes December 10, 2025
Reprogramming immunity to rewrite the story of Type 1 ...
With Breakthrough T1D funding, an MUSC researcher will study therapeutic options that address the underlying causes of type 1 diabetes. By Sophia Barry Gordon January 07, 2026 * Share * * *
What can pancreatic function tell us about how quickly type 1 diabetes develops? | Breakthrough T1D UK
We are funding Dr Kathleen Gillespie and her team at the University of Bristol to investigate whether existing tests, used to measure how well the pancreas works, can be used to help predict how qu...
An AI-driven bioelectronics system to accelerate SC-islet maturation - Breakthrough T1D
Transplantable pancreatic islets differentiated from human pluripotent stem cells (SC-islets) are likely to become a broad therapeutic option for severe type 1 diabetes (T1D) but suffer from underd...
Multidimensional Pancreatic Islet β-cell Function (PIF) Assessment Improves Predictive Effect of Diabetes Risk Scores - PubMed
**Aims/hypothesis:** Comprehensive assessment of pancreatic islet β-cell function (PIF) is crucial for diabetes management. We proposed a multidimensional, relative quantification system for PIF me...
Code & Tools
**G2P2C**is a project to develop Reinforcement Learning (RL)-based Artificial Pancreas Systems (APS), with the aim to automate treatment in Type 1 ...
## About GluCoEnv - Glucose Control Environment, is a simulation environment which aims to facilitate the development of Reinforcement Learning bas...
A Type-1 Diabetes simulator implemented in Python for Reinforcement Learning purpose
This repository contains the code and data for calibrating the natural history of pancreatic cancer (PC) in patients with new onset diabetes (NOD) ...
Artificial Pancreas was implemented using an ANN that maintains the glucose levels of patients with type 1 diabetes in an optimal range. The neural...
Recent Preprints
The role of the beta cell in type 2 diabetes - PubMed Central
Recent advances in genome-wide approaches, the availability of isolated human islets for research and the evaluation of novel incretin mimetics in large clinical trials have brought about remarkabl...
Diabetes reshapes pancreatic cancer-associated ...
Approximately half of pancreatic cancer patients present with comorbid diabetes. Diabetes is correlated with adverse prognostic outcomes in pancreatic cancer patients, but the underlying mechanism ...
Pancreatic Cancer and Diabetes: Insights, Hypotheses, ...
Pancreatic ductal adenocarcinoma (PDAC) is frequently associated with new-onset diabetes (NOD) in adults aged ≥ 50 years. Accordingly, NOD may serve as an early clinical marker for PDAC, although t...
Pancreatic Islet Cell Hormones: Secretion, Function, and ...
# Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy Jinfang Ma ### Jinfang Ma
Latest Developments
Recent developments in pancreatic function and diabetes research include the discovery that pancreatic alpha cells produce GLP-1, a hormone that boosts insulin and may influence diabetes treatment, and advances in cell therapy approaches that have cured autoimmune Type 1 diabetes in mice through immune system reset and pancreatic islet transplants (Duke University, Stanford Medicine, as of September and November 2025). Additionally, research has identified early loss of small insulin-producing beta cell clusters in Type 1 diabetes progression, and new therapies show promise in reducing or eliminating the need for insulin injections (UF Health, Science News, July 2025).
Sources
Frequently Asked Questions
What is meant by β-cell dysfunction in diabetes research?
β-cell dysfunction refers to impaired insulin secretion and/or reduced β-cell functional capacity within pancreatic islets, leading to inadequate control of glucose homeostasis in diabetes mellitus. Work in this topic commonly interprets β-cell failure through cellular stress and survival pathways discussed in "Signal integration in the endoplasmic reticulum unfolded protein response" (2007) and "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1" (2011).
How do SGLT2 inhibitor outcome trials inform research on pancreatic function in type 2 diabetes?
SGLT2 inhibitor trials show that altering systemic glucose handling can change cardiovascular and renal outcomes that are central to diabetes morbidity, providing clinical constraints for mechanistic models of islet dysfunction and compensation. "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes" (2017) and "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes" (2018) explicitly evaluated cardiovascular endpoints in people with type 2 diabetes while using glucose-lowering therapy.
Which papers from the list are most directly useful for understanding diabetes-related kidney and heart outcomes?
For kidney outcomes in diabetic nephropathy, "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy" (2019) reported lower risks of kidney failure and cardiovascular events with a median follow-up of 2.62 years. For heart failure outcomes, "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction" (2019) reported reduced risk of worsening heart failure or cardiovascular death regardless of diabetes status.
How is incretin-based therapy connected to pancreatic endocrine function in this paper set?
Incretin-based therapy is connected to pancreatic endocrine function because it modulates insulin secretion physiology and is evaluated for hard clinical outcomes in diabetes populations. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes" (2016) reported a lower rate of the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with liraglutide than with placebo.
Why are ER stress and autophagy repeatedly cited in discussions of β-cell survival and insulin secretion?
ER stress and autophagy are repeatedly cited because β-cells are professional secretory cells and thus sensitive to perturbations in protein folding and nutrient signaling, which can affect insulin biosynthesis and cell viability. "Signal integration in the endoplasmic reticulum unfolded protein response" (2007) provides a framework for how UPR signaling is integrated, while "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1" (2011) describes a direct molecular mechanism linking energy sensing to autophagy control.
Which highly cited discovery links energy balance biology to obesity-related diabetes risk in this list?
"Positional cloning of the mouse obese gene and its human homologue" (1994) is a highly cited discovery that connects genetic control of energy balance to pathways that influence obesity, a major risk factor for type 2 diabetes. The paper is foundational for mechanistic thinking about how adiposity-related signals can intersect with insulin resistance and β-cell demand.
Open Research Questions
- ? How do ER stress signaling principles summarized in "Signal integration in the endoplasmic reticulum unfolded protein response" (2007) map onto β-cell-specific thresholds for reversible dysfunction versus irreversible loss in diabetes?
- ? Which autophagy control nodes described in "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1" (2011) are most predictive of preserved insulin secretory capacity under chronic nutrient excess typical of type 2 diabetes?
- ? What mechanistic pathways best explain the cardiovascular and renal benefits observed with SGLT2 inhibitors in "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes" (2017), "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes" (2018), and "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy" (2019), and how should those pathways be incorporated into integrated models of pancreatic endocrine dysfunction?
- ? How should incretin-based outcome evidence from "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes" (2016) be reconciled with β-cell-centric models of diabetes progression that emphasize declining insulin secretion capacity?
- ? Which upstream determinants of obesity-related metabolic load implied by "Positional cloning of the mouse obese gene and its human homologue" (1994) best predict the point at which β-cell compensation fails and clinical diabetes emerges?
Recent Trends
Across a very large body of work (132,706 papers), the most-cited anchors in this provided set emphasize a shift toward evaluating diabetes therapies by cardiovascular and renal outcomes alongside glycemic effects.
This is reflected by the prominence of outcome trials including "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes" , "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes" (2017), "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes" (2018), and "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy" (2019), with the latter explicitly reporting benefits at a median follow-up of 2.62 years.
2016In parallel, mechanistic framing papers—"Signal integration in the endoplasmic reticulum unfolded protein response" and "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1" (2011)—remain central because they provide interpretable cellular pathways that can be linked to β-cell secretory stress, survival, and adaptation when attempting to explain why therapies affect heart and kidney outcomes in diabetes populations.
2007Research Pancreatic function and diabetes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pancreatic function and diabetes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers